Clinical trials: Hydrocortisone
Cushing's Disease
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
This study will evaluate the safety and efficacy of two different doses of Pasireotide in patients with de novo or recurrent/persistent Cushing's Disease.
- Trial name
- NCT00434148
- Testing
- Pasireotide
- Where
- 68 sites in United States, Argentina and 16 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms
Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer
To compare the efficacy of both strategies (reference treatment: Docetaxel+Prednisone and experimental treatment: Docetaxel+Estramustine+Hydrocortisone) by means of PSA values.
- Trial name
- PROSTATA (NCT00705822)
- Testing
- Docetaxel + Estramustine + Hydrocortisone, Docetaxel + Prednisone
- Where
- Spain
- Volunteers
- 54 people
- Sponsor
- Sanofi
Smith Magenis Syndrome
Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With Smith-Magenis Syndrome (SMS)
The purpose of this study is to characterize the circadian rhythm disruption experienced by patients as determined by plasma melatonin, cortisol, and other circadian analytes
- Trial name
- NCT02180451
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Vanda Pharmaceuticals
Atopic Dermatitis
Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis
Seven-month study in pediatric patients (2-11 years) with moderate to severe AD who were considered to benefit from vaccination to prevent invasive disease caused by Neisseria meningitides serogroup C.
- Trial name
- NCT00801957
- Testing
- tacrolimus ointment 0.03%, hydrocortisone acetate ointment 1%, hydrocortisone butyrate ointment 0.1%
- Where
- 36 sites in Australia, Belgium and 6 more
- Volunteers
- 260 people
- Sponsor
- Astellas Pharma Inc
Cushing Disease
Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma.
- Trial name
- NCT00171951
- Testing
- Pasireotide
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Adrenal Insufficiency
Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modified-release hydrocortisone in comparison to…
- Trial name
- NCT00915343
- Testing
- hydrocortisone (modified release), oral tablet 20 and 5 mg, Hydrocortisone, oral tablet, 10 mg
- Volunteers
- 64 people
- Sponsor
- Shire
Adrenal Insufficiency
Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration
This is a single centre, open-label, randomised, single dose, three-period, crossover study to evaluate the bioavailability of Infacort® administered as 'sprinkles' with soft food and yoghurt compared with direct administration…
- Trial name
- NCT03178214
- Testing
- Infacort
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Neurocrine UK Limited
Primary Adrenal Insufficiency
Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency
This study is a double-blind, double-dummy, two-way cross-over, randomised, Phase II study to be conducted at approximately 6 investigational sites in 2 countries.
- Trial name
- CHAMPAIN (NCT05222152)
- Testing
- Chronocort, Plenadren
- Where
- 8 sites in Germany, United Kingdom
- Volunteers
- 58 people
- Sponsor
- Neurocrine UK Limited
Erythema, Pain
Ultra Violet B Radiation (UVR) Study of Strontium Chloride Hexahydrate Hydrocortisone
Double blinded (subject and observer), randomised, active (hydrocortisone (HC)) controlled study of the effect of strontium chloride hexahydrate on ultraviolet B radiation (UVR) induced signs of inflammation (erythema and pain)…
- Trial name
- NCT01301677
- Testing
- Hydrocortisone, 2PX+, 2PX-
- Where
- 2 sites in Germany
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- X-pert Med GmbH
Hemorrhoids
Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II Hemorrhoids
The objectives of this study are to assess the potential contribution of lidocaine hydrochloride or hydrocortisone acetate, alone or in combination, in topical cream preparations in the treatment of Grade I or II hemorrhoids and…
- Trial name
- Hydro/Lido (NCT02689856)
- Testing
- Hydrocortisone acetate and lidocaine hydrochloride, Hydrocortisone acetate, Lidocaine hydrochloride
- Volunteers
- 211 people
- Sponsor
- Citius Pharmaceuticals, Inc.
Smoking Cessation, Tobacco Use Disorder
Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment
This open-label study will evaluate EMB-001, comprised of metyrapone, a cortisol synthesis inhibitor marketed as a diagnostic drug for testing hypothalamic-pituitary-adrenal (HPA) axis function, combined with oxazepam, an…
- Trial name
- NCT04868253
- Testing
- EMB-01
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Adrenal Insufficiency
Extension Study for Patients Entered Into Study Infacort 003
A Phase 3, open-label, single-group, non-randomised, observational study of the safety and biochemical disease control of Infacort® in neonates, infants and children with adrenal insufficiency and congenital adrenal hyperplasia…
- Trial name
- NCT02733367
- Testing
- Infacort®
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Neurocrine UK Limited
Congenital Adrenal Hyperplasia, 21-Hydroxylase Deficiency
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
This study will test a new, extended release form of hydrocortisone called Chronocort in patients with congenital adrenal hyperplasia (CAH).
- Conditions
- Congenital Adrenal Hyperplasia, 21-Hydroxylase Deficiency, Adrenogenital Syndrome
- Trial name
- NCT00519818
- Testing
- Chronocort, Cortef
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Neurocrine UK Limited
Internal Hemorrhoids
Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids
A randomized, double-blind, placebo-controlled, multicenter, parallel group study of the safety and efficacy of Hydrocortisone Acetate Suppositories, 25 mg compared to placebo suppositories in the treatment of symptomatic…
- Trial name
- NCT03335774
- Testing
- Hydrocortisone Acetate Suppository, 25 mg (Nivagen)
- Where
- 2 sites in United States, India
- Volunteers
- 103 people
- Sponsor
- Nivagen Pharmaceuticals Inc.
Metastatic Castration-resistant Prostate Cancer
MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer/androgen pathway modulator refractory (mCRPC/APMR). Current treatment for mCRPC includes chemotherapy, such as docetaxel.
- Trial name
- TroFuse-01A (NCT07908524)
- Testing
- Sacituzumab tirumotecan, Rescue medication, Docetaxel
- Volunteers
- 290 people
- Sponsor
- Merck Sharp & Dohme LLC
Necrotizing Soft Tissue Infection, Sepsis
HAT for the Treatment of Sepsis Associated With NASTI
Evaluate the impact of HAT therapy versus placebo in the treatment of patients with an acute NSTI and sepsis.
- Trial name
- NCT05157360
- Testing
- HAT
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ascension Health
Hypertension
A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension
This study determined the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in participants with hypertension.
- Trial name
- NCT00817414
- Testing
- LCI699
- Where
- 11 sites in United States, Iceland
- Volunteers
- 63 people
- Sponsor
- Novartis
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body.
- Trial name
- NCT00640822
- Testing
- Calcipotriol plus hydrocortisone ointment vehicle, Tacalcitol Ointment, Calcipotriol plus hydrocortisone ointment
- Where
- 3 sites in Canada, France and 1 more
- Volunteers
- 782 people
- Sponsor
- LEO Pharma
Irritable Bowel Syndrome
A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679
To better understand the way that GW876008 and GSK561679 work on hormone responses in patients with Irritable Bowel Syndrome.
- Trial name
- NCT00511563
- Testing
- GW876008 and GSK561679
- Sponsor
- GlaxoSmithKline
Cocaine Dependence, Cocaine Addiction
A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction
Subjects will be randomly assigned to receive either one of the two potential dose combinations of the study medications or placebo over 6 weeks.
- Trial name
- NCT00567814
- Testing
- Metyrapone, Oxazepam
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Embera NeuroTherapeutics, Inc.